HEIDRICH A GRANT III 4
4 · TULARIK INC · Filed Aug 17, 2004
Insider Transaction Report
Form 4
TULARIK INCTLRK
HEIDRICH A GRANT III
Director
Transactions
- Disposition to Issuer
Common Stock
2004-08-13−27,284→ 0 total - Disposition to Issuer
Common Stock
2004-08-13−125,961→ 0 total(indirect: TTEE) - Disposition to Issuer
Stock Option (right to buy)
2004-08-13−8,000→ 0 totalExercise: $25.38Exp: 2010-04-26→ Common Stock (8,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2004-08-13−10,000→ 0 totalExercise: $14.40Exp: 2012-04-17→ Common Stock (10,000 underlying)
Footnotes (8)
- [F1]Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 12,305 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement.
- [F2]Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 56,808 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement.
- [F3]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of all such equity securities covered by this statement.
- [F4]The Reporting Person is a trustee of certain family trusts.
- [F5]This option, which was fully vested as of April 26, 2004, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 3,608 shares of Amgen common stock for $56.27 per share.
- [F6]This option, which provided for vesting in equal annual installments over a four-year period until full vest on April 24, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 3,608 shares of Amgen common stock for $46.41 per share.
- [F7]This option, which provided for vesting in equal annual installments over a four-year period until full vest on April 18, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 4,510 shares of Amgen common stock for $31.93 per share.
- [F8]This option, which provided for vesting in equal annual installments over a four-year period until full vest on April 23, 2007, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 4,510 shares of Amgen common stock for $11.47 per share.